J. Despres and I. Lemieux, Abdominal obesity and metabolic syndrome, Nature, vol.322, issue.7121, pp.881-887, 2006.
DOI : 10.1038/nature05488

D. Haslam and W. James, Obesity, The Lancet, vol.366, issue.9492, pp.1197-1209, 2005.
DOI : 10.1016/S0140-6736(05)67483-1

S. Parekh and F. Anania, Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.132, issue.6, pp.2191-2207, 2007.
DOI : 10.1053/j.gastro.2007.03.055

S. Weisberg, D. Mccann, M. Desai, M. Rosenbaum, and R. Leibel, Obesity is associated with macrophage accumulation in adipose tissue, Journal of Clinical Investigation, vol.112, issue.12, pp.1796-1808, 2003.
DOI : 10.1172/JCI19246DS1

G. Hotamisligil, Inflammation and metabolic disorders, Nature, vol.314, issue.7121, pp.860-867, 2006.
DOI : 10.1038/nature05485

S. Shoelson, L. Herrero, and A. Naaz, Obesity, Inflammation, and Insulin Resistance, Gastroenterology, vol.132, issue.6, pp.2169-2180, 2007.
DOI : 10.1053/j.gastro.2007.03.059

H. Xu, G. Barnes, Q. Yang, G. Tan, and D. Yang, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, Journal of Clinical Investigation, vol.112, issue.12, pp.1821-1830, 2003.
DOI : 10.1172/JCI19451DS1

T. Nomiyama, D. Perez-tilve, D. Ogawa, F. Gizard, and Y. Zhao, Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice, Journal of Clinical Investigation, vol.117, issue.10, pp.2877-2888, 2007.
DOI : 10.1172/JCI31986DS1

A. Bertola, V. Deveaux, S. Bonnafous, D. Rousseau, and R. Anty, Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid Obesity, Diabetes, vol.58, issue.1, pp.125-133, 2009.
DOI : 10.2337/db08-0400

URL : https://hal.archives-ouvertes.fr/hal-00419058

C. Postic and J. Girard, Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice, Journal of Clinical Investigation, vol.118, issue.3, pp.829-838, 2008.
DOI : 10.1172/JCI34275

D. Marzo and V. , Targeting the endocannabinoid system: to enhance or reduce?, Nature Reviews Drug Discovery, vol.1761, issue.5, pp.438-455, 2008.
DOI : 10.1038/sj.bjp.0706971

A. Mallat and S. Lotersztajn, Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver, AJP: Gastrointestinal and Liver Physiology, vol.294, issue.1, pp.9-12, 2008.
DOI : 10.1152/ajpgi.00467.2007

P. Pacher, S. Batkai, and G. Kunos, The Endocannabinoid System as an Emerging Target of Pharmacotherapy, Pharmacological Reviews, vol.58, issue.3, pp.389-462, 2006.
DOI : 10.1124/pr.58.3.2

G. Kunos and D. Osei-hyiaman, Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis, AJP: Gastrointestinal and Liver Physiology, vol.294, issue.5, pp.1101-1104, 2008.
DOI : 10.1152/ajpgi.00057.2008

T. Klein, Cannabinoid-based drugs as anti-inflammatory therapeutics, Nature Reviews Immunology, vol.267, issue.5, pp.400-411, 2005.
DOI : 10.1002/glia.10177

S. Steffens, N. Veillard, C. Arnaud, G. Pelli, and F. Burger, Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice, Nature Medicine, vol.434, pp.782-786, 2005.

S. Lotersztajn, F. Teixeira-clerc, B. Julien, V. Deveaux, and Y. Ichigotani, CB2 receptors as new therapeutic targets for liver diseases, British Journal of Pharmacology, vol.171, issue.2, pp.286-289, 2008.
DOI : 10.1038/sj.bjp.0707511

S. Batkai, D. Osei-hyiaman, H. Pan, O. El-assal, and M. Rajesh, Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury, The FASEB Journal, vol.21, issue.8, pp.1788-1800, 2007.
DOI : 10.1096/fj.06-7451com

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228252

N. Buckley, K. Mccoy, E. Mezey, T. Bonner, and A. Zimmer, Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor, European Journal of Pharmacology, vol.396, issue.2-3, pp.141-149, 2000.
DOI : 10.1016/S0014-2999(00)00211-9

P. Even, E. Perrier, J. Aucouturier, and S. Nicolaidis, Utilisation of the method of Kalman filtering for performing the on-line computation of background metabolism in the free-moving, free-feeding rat, Physiology & Behavior, vol.49, issue.1, pp.177-187, 1991.
DOI : 10.1016/0031-9384(91)90252-J

P. Even, A. Mokhtarian, and A. Pele, Practical aspects of indirect calorimetry in laboratory animals, Neuroscience & Biobehavioral Reviews, vol.18, issue.3, pp.435-447, 1994.
DOI : 10.1016/0149-7634(94)90056-6

C. Knauf, P. Cani, C. Perrin, M. Iglesias, and J. Maury, Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage, Journal of Clinical Investigation, vol.115, issue.12, pp.3554-3563, 2005.
DOI : 10.1172/JCI25764

B. Julien, P. Grenard, F. Teixeira-clerc, V. Nhieu, J. Li et al., Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, vol.128, issue.3, pp.742-755, 2005.
DOI : 10.1053/j.gastro.2004.12.050

J. Huffman, J. Liddle, S. Yu, M. Aung, and M. Abood, 3-(1???,1???-Dimethylbutyl)-1-deoxy-??8-THC and related compounds: synthesis of selective ligands for the CB2 receptor, Bioorganic & Medicinal Chemistry, vol.7, issue.12, pp.2905-2914, 1999.
DOI : 10.1016/S0968-0896(99)00219-9

N. Defer, J. Wan, R. Souktani, B. Escoubet, and M. Perier, The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy, The FASEB Journal, vol.23, issue.7, 2009.
DOI : 10.1096/fj.09-129478

URL : https://hal.archives-ouvertes.fr/inserm-00371859

R. Pertwee, G. Griffin, S. Fernando, X. Li, and A. Hill, AM630, a competitive cannabinoid receptor antagonist, Life Sciences, vol.56, issue.23-24, pp.1949-1955, 1995.
DOI : 10.1016/0024-3205(95)00175-6

N. Kamei, T. K. Suzuki, R. Ohsugi, M. Watanabe, and T. , Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance, Journal of Biological Chemistry, vol.281, issue.36, pp.26602-26614, 2006.
DOI : 10.1074/jbc.M601284200

H. Kanda, S. Tateya, Y. Tamori, K. Kotani, and K. Hiasa, MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity, Journal of Clinical Investigation, vol.116, issue.6, pp.1494-1505, 2006.
DOI : 10.1172/JCI26498DS1

R. Roche, L. Hoareau, S. Bes-houtmann, M. Gonthier, and C. Laborde, Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes, Histochemistry and Cell Biology, vol.346, issue.1, pp.177-187, 2006.
DOI : 10.1007/s00418-005-0127-4

I. Matias, M. Gonthier, P. Orlando, V. Martiadis, D. Petrocellis et al., Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and ??-Pancreatic Cells and in Obesity and Hyperglycemia, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.3171-3180, 2006.
DOI : 10.1210/jc.2005-2679

A. Miller and N. Stella, receptor-mediated migration of immune cells: it can go either way, British Journal of Pharmacology, vol.6, issue.2, pp.299-308, 2008.
DOI : 10.1038/sj.bjp.0707523

F. Montecucco, F. Burger, F. Mach, and S. Steffens, CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways, AJP: Heart and Circulatory Physiology, vol.294, issue.3, pp.1145-1155, 2008.
DOI : 10.1152/ajpheart.01328.2007

J. Derocq, O. Jbilo, M. Bouaboula, M. Segui, and C. Clere, Genomic and Functional Changes Induced by the Activation of the Peripheral Cannabinoid Receptor CB2 in the Promyelocytic Cells HL-60. POSSIBLE INVOLVEMENT OF THE CB2 RECEPTOR IN CELL DIFFERENTIATION, Journal of Biological Chemistry, vol.275, issue.21, pp.15621-15628, 2000.
DOI : 10.1074/jbc.275.21.15621

P. Cavuoto, A. Mcainch, G. Hatzinikolas, D. Cameron-smith, and G. Wittert, Effects of cannabinoid receptors on skeletal muscle oxidative pathways, Molecular and Cellular Endocrinology, vol.267, issue.1-2, pp.63-69, 2007.
DOI : 10.1016/j.mce.2006.12.038

K. Starowicz, L. Cristino, I. Matias, R. Capasso, and A. Racioppi, Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet, Obesity, vol.15, issue.3, pp.553-565, 2008.
DOI : 10.1038/oby.2007.106

P. Juan-pico, E. Fuentes, F. Bermudez-silva, J. Diaz-molina, F. Ripoll et al., Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic ??-cell, Cell Calcium, vol.39, issue.2, pp.155-162, 2006.
DOI : 10.1016/j.ceca.2005.10.005

S. Weisberg, D. Hunter, R. Huber, J. Lemieux, and S. Slaymaker, CCR2 modulates inflammatory and metabolic effects of high-fat feeding, Journal of Clinical Investigation, vol.116, issue.5, pp.115-124, 2006.
DOI : 10.1172/JCI24335C1

S. Engeli, J. Bohnke, M. Feldpausch, K. Gorzelniak, and J. Janke, Activation of the Peripheral Endocannabinoid System in Human Obesity, Diabetes, vol.54, issue.10, pp.2838-2843, 2005.
DOI : 10.2337/diabetes.54.10.2838

M. Gonthier, L. Hoareau, F. Festy, I. Matias, and M. Valenti, Identification of Endocannabinoids and Related Compounds in Human Fat Cells*, Obesity, vol.173, issue.4, pp.837-845, 2007.
DOI : 10.1016/j.cyto.2006.06.005

M. Bluher, S. Engeli, N. Kloting, J. Berndt, and M. Fasshauer, Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity, Diabetes, vol.55, issue.11, pp.3053-3060, 2006.
DOI : 10.2337/db06-0812

M. Cote, I. Matias, I. Lemieux, S. Petrosino, and N. Almeras, Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, Int J Obes (Lond), vol.31, pp.692-699, 2007.

M. Gary-bobo, G. Elachouri, J. Gallas, P. Janiak, and P. Marini, Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1, pp.122-129, 2007.
DOI : 10.1002/hep.21641

W. Jeong, D. Osei-hyiaman, O. Park, J. Liu, and S. Batkai, Paracrine Activation of Hepatic CB1 Receptors by??Stellate Cell-Derived Endocannabinoids Mediates??Alcoholic Fatty Liver, Cell Metabolism, vol.7, issue.3, pp.227-235, 2008.
DOI : 10.1016/j.cmet.2007.12.007

L. Bellocchio, G. Mancini, V. Vicennati, R. Pasquali, and U. Pagotto, Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases, Current Opinion in Pharmacology, vol.6, issue.6, pp.586-591, 2006.
DOI : 10.1016/j.coph.2006.09.001

C. Hezode, F. Roudot-thoraval, S. Nguyen, P. Grenard, and B. Julien, 68 Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C, Journal of Hepatology, vol.40, pp.63-71, 2005.
DOI : 10.1016/S0168-8278(04)90068-2

F. Teixeira-clerc, B. Julien, P. Grenard, J. Tran-van-nhieu, and V. Deveaux, CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, Nature Medicine, vol.30, issue.6, pp.671-676, 2006.
DOI : 10.1038/nm1421

C. Hezode, E. Zafrani, F. Roudot-thoraval, C. Costentin, and A. Hessami, Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C, Gastroenterology, vol.134, issue.2, pp.432-439, 2008.
DOI : 10.1053/j.gastro.2007.11.039

A. Mallat and S. Lotersztajn, Endocannabinoids as novel mediators of liver diseases, Journal of Endocrinological Investigation, vol.29, pp.58-65, 2006.